Atrium Therapeutics, Inc.
RNA
$13.19
$0.413.21%
NASDAQ
| 03/31/2026 | |||||
|---|---|---|---|---|---|
| Revenue | 2,185.80% | ||||
| Total Other Revenue | -- | ||||
| Total Revenue | 2,185.80% | ||||
| Cost of Revenue | -24.41% | ||||
| Gross Profit | 165.79% | ||||
| SG&A Expenses | 29.25% | ||||
| Depreciation & Amortization | -- | ||||
| Other Operating Expenses | -- | ||||
| Total Operating Expenses | 23.21% | ||||
| Operating Income | 40.62% | ||||
| Income Before Tax | 42.85% | ||||
| Income Tax Expenses | -- | ||||
| Earnings from Continuing Operations | 42.91% | ||||
| Earnings from Discontinued Operations | -- | ||||
| Extraordinary Item & Accounting Change | -- | ||||
| Minority Interest in Earnings | -- | ||||
| Net Income | 42.91% | ||||
| EBIT | 40.62% | ||||
| EBITDA | 40.89% | ||||
| EPS Basic | 48.22% | ||||
| Normalized Basic EPS | 48.16% | ||||
| EPS Diluted | 48.22% | ||||
| Normalized Diluted EPS | 48.16% | ||||
| Average Basic Shares Outstanding | 10.25% | ||||
| Average Diluted Shares Outstanding | 10.25% | ||||
| Dividend Per Share | -- | ||||
| Payout Ratio | -- | ||||